Claims
- 1. A method for determining the presence or absence of a pathological cell in a patient, said method comprising detecting a nucleic acid comprising a sequence at least 80% identical to a sequence as described in Tables 2A-80 in a biological sample from said patient, thereby determining the presence or absence of said pathological cell.
- 2. The method of claim 1, wherein:
a) said pathology is described in Table 1, including a cancer; and/or b) said biological sample comprises isolated nucleic acids.
- 3. The method of claim 1, wherein said biological sample is tissue from an organ which is affected by said pathology of Table 1, including a cancer.
- 4. The method of claim 2, wherein said nucleic acids are mRNA
- 5. The method of claim 2:a) further comprising a step of amplifying nucleic acids before said step of detecting said nucleic acid; or b) where said detecting is of a protein encoded by said nucleic acid.
- 6. The method of claim 1, wherein said nucleic acid comprises a sequence as described in Tables 2A-80.
- 7. The method of claim 2, wherein:
a) said detecting step is carried out by:
i) using a labeled nucleic acid probe; ii) utilizing a biochip comprising a sequence at least 80% identical to a sequence as described in Tables 2A-80; or iii) detecting a polypeptide encoded by said nucleic acid; or b) said patient is:
i) undergoing a therapeutic regimen to treat said pathology of Table 1; or ii) is suspected of having said pathology or cancer.
- 8. An isolated nucleic acid molecule comprising a sequence as described in Tables 2A-80.
- 9. The nucleic acid molecule of claim 8, which is labeled.
- 10. An expression vector comprising the nucleic acid of claim 8.
- 11. A host cell comprising the expression vector of claim 10.
- 12. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a sequence as described in Tables 2A-80.
- 13. An antibody that specifically binds a polypeptide of claim 12.
- 14. The antibody of claim 13:a) conjugated to an effector component; b) conjugated to a detectable label, including a fluorescent label, a radioisotope, or a cytotoxic chemical; c) which is an antibody fragment; or d) which is a humanized antibody.
- 15. A method for specifically targeting a compound to a pathological cell in a patient, said method comprising administering to said patient an antibody of claim 13, thereby providing said targetting.
- 16. A method for determining the presence or absence of a pathological cell in a patient, said method comprising contacting a biological sample with an antibody of claim 13.
- 17. The method of claim 16, wherein:
a) said antibody is conjugated to:
i) an effector component; or ii) a fluorescent label; or b) said biological sample is a blood, serum, urine, or stool sample.
- 18. A method for identifying a compound that modulates a pathology-associated polypeptide, said method comprising the steps of:
a) contacting said compound with a pathology-associated polypeptide, said polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as described in Tables 2A-80; and b) determining the functional effect of said compound upon said polypeptide.
- 19. A drug screening assay comprising the steps of:
a) administering a test compound to a mammal having a pathology of Table 1 or a cell isolated therefrom; and b) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as described in Tables 2A-80 in a treated cell or mammal with the level of gene expression of said polynucleotide in a control cell or mammal, wherein a test compound that modulates said level of expression of the polynucleotide is a candidate for the treatment of said pathology.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Ser. No. 60/340,376, filed Dec. 14, 2001; Attorney Docket Number 018501-006400US, filed Feb. 8, 2002; U.S. Ser. No. 60/347,211, filed Jan. 8, 2002; U.S. Ser. No. 60/334,393, filed Nov. 29, 2001; U.S. Ser. No. 60/335,394, filed Nov. 15, 2001; U.S. Ser. No. 60/347,349, filed Jan. 10, 2002; U.S. Ser. No. 60/368,809, filed Mar. 29, 2002; U.S. Ser. No. 60/409,450, filed Sep. 9, 2002; U.S. Ser. No. 60/359,077, filed Feb. 20, 2002; U.S. Ser. No. 60/386,614, filed Jun. 5, 2002; U.S. Ser. No. 60/356,714, filed Feb. 13, 2002; U.S. Ser. No. 60/397,775 filed Jul. 22, 2002; U.S. Ser. No. 60/332,464, filed Nov. 21, 2001; U.S. Ser. No. 60/397,845, filed Jul. 22, 2002; U.S. Ser. No. 60/370,110, filed Apr. 4, 2002; U.S. Ser. No. 60/396,839, filed Jul. 16, 2002; U.S. Ser. No. 60/350,666, filed Nov. 13, 2001; and U.S. Ser. No. 60/372,246, filed Apr. 12, 2002; each of which is incorporated herein by reference for all purposes. The application also incorporates by reference PCT/US02/29560; PCT/US02/02242; and PCT/US02/17594.
Provisional Applications (17)
|
Number |
Date |
Country |
|
60409450 |
Sep 2002 |
US |
|
60397775 |
Jul 2002 |
US |
|
60397845 |
Jul 2002 |
US |
|
60396839 |
Jul 2002 |
US |
|
60386614 |
Jun 2002 |
US |
|
60370110 |
Apr 2002 |
US |
|
60368809 |
Mar 2002 |
US |
|
60359077 |
Feb 2002 |
US |
|
60356714 |
Feb 2002 |
US |
|
60347349 |
Jan 2002 |
US |
|
60347211 |
Jan 2002 |
US |
|
60340376 |
Dec 2001 |
US |
|
60334393 |
Nov 2001 |
US |
|
60332464 |
Nov 2001 |
US |
|
60335394 |
Dec 2001 |
US |
|
60350666 |
Nov 2001 |
US |
|
60372246 |
Apr 2002 |
US |